QUOTE AND NEWS
SeekingAlpha  Sep 15  Comment 
By Kevin Quon: Progress appears to be underway for Solazyme (SZYM) when it comes to its new food ingredient brand of AlgaVia. In Solazyme's latest conference call, management announced that the company had signed "an important customer" for...
Motley Fool  Sep 8  Comment 
Investors had grand plans for Solazyme in the beginning of the year. Then reality took over.
Forbes  Aug 29  Comment 
Wall Street has never been known for its patience. When innovative companies do not deliver results on schedule, their stocks can take a beating. This recently happened to Solazyme (NASDAQ: SZYM), and Marketocracy Master Justin Uyehara believes...
SeekingAlpha  Aug 20  Comment 
By Kevin Quon: A reinvigorated consumer pursuit towards sustainability has placed companies on the pathway to find alternatives to palm oil. One such option that is beginning to emerge is the use of algal oil to replace the base materials found...
Motley Fool  Aug 12  Comment 
Anti-aging cream from Solazyme needs a little help to reach 2014 revenue targets. Ulta Salon and Nordstrom may provide the boost it needs.
Motley Fool  Aug 8  Comment 
Solazyme has ambitious plans for its renewable oils platform, but it needs to bring initial capacity online before it can replace petroleum.
Biomass Magazine  Aug 5  Comment 
Solazyme Inc. announced optimistic results for second quarter 2014 with total revenue at $15.9 million compared with $11.2 million in the second quarter of 2013, an increase of 43 percent. Second quarter GAAP net loss was $42.9 million.
SeekingAlpha  Jul 30  Comment 
The following audio is from a conference call that will begin on July 30, 2014 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Motley Fool  Jul 15  Comment 
The favorite and most important equipment at Moema supports fermentation. What Solazyme investors need to know.
SeekingAlpha  Jul 14  Comment 
By Kevin Quon: When it comes to oil & gas exploration, it is often difficult to find green companies that are advancing a sustainable business in this industry. Yet for renewable oils and bioproducts producer, Solazyme (NASDAQ:SZYM), the mission...




 
TOP CONTRIBUTORS


Solazyme (NASDAQ:SZYM) transforms plant-based sugars into petroleum-based products for the chemical industry, fuels, nutrition and skin and personal care products and is scaling up manufacturing capacity in order to better serve these markets. In order to alleviate the manufacturing capacity constraint, Solazyme uses a mixed operational strategy approach including contract manufacturing, and joint ventures. The company's primary revenues are derived from producing oil via an indirect photosynthesis technology. As opposed to common open-pond and photo bio reactor approach, Solazyme uses feeds sugars to proprietary oil-producing micro-algae in a dark fermentation tank to accelerate normal production time. [1]

The rapidly growing demand and depleting supply for oils in today's society has created a need to look to alternatives sources of oil. As a whole, the alternative fuel industry has several advantages including the ability to scale production in order to minimize price variability. The controlled bio reactor production technology also enables company's like Solazyme to produce tailored, high-end fuels for specialized markets.

[2]

The company's initial public offering of stock on the NASDAQ occurred on May 27, 2011. The company offered 11M shares each for $18, which was at the high end of the $15-$17 price range. The offering raised a total of $198M. The lead managers of the IPO were Morgan Stanley (MS) and Goldman Sachs Group (GS).[3]

During the full year 2010, the company reported a total revenue of $38M and incurred a net loss of $16M. This represents a 400% increase in total revenue and a 19% increase in net loss with respect to 2009. [4]

  1. SYZM S-1/A 2011 PROSPECTUS SUMMARY "Prospectus Summary" pg 1-3
  2. SYZM S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg 1-6
  3. Renaissance Capital - IPO Home "Solazyme prices upsized IPO at $18, above the range" 27 May 2011
  4. SYZM S-1/A 2011 PROSPECTUS SUMMARY "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 9
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki